Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Platinum compounds play a central role in cancer chemotherapy. Although treatment is limited by side effects, they continue to have widespread application. One of the main aims of clinical or translational research in cancer is the search for genetic factors that could foresee treatment outcomes, in biologic activity and toxic effects. This genetic analysis might allow selection of patients who will have the greatest benefit from chemotherapy. Furthermore, a better knowledge of the underlying molecular profile of the host and the tumor will facilitate screening for lung cancer susceptibility and tailoring of chemotherapy in individual patients, choosing those most likely to respond, adjusting doses more precisely in order to reduce less adverse effects, and establishing safety profiles based on individual genetic analyses. Herein, we discuss current knowledge regarding gene expression and polymorphisms of DNA repair enzymes in regard to cancer susceptibility and response to chemotherapy.

Original publication




Journal article


Clinical lung cancer

Publication Date





369 - 375


Servicio de Oncología Médica, Hospital General Universitario, Valencia, Spain, Laboratorio de Oncología Molecular, Fundación Investigación, Hospital General Universitario, Valencia, Spain.


Humans, Carcinoma, Squamous Cell, Lung Neoplasms, Cisplatin, DNA Repair Enzymes, Antineoplastic Agents, Gene Expression Regulation, Enzymologic, Polymorphism, Single Nucleotide